Upcoming clinical trial of PSMA-linked lutetium-177 in recurrent mCRPC

According to a recent media release, a company called Endocyte has reached agreement with the US Food and Drug Administration about the design of a pivotal Phase III clinical trial that will test the effectiveness and safety of 177Lu-PSMA-617 in men with recurrent, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Ac-225-PSMA-617 apparently extends survival of very late-stage patients: an update

The nuclear medicine group at the University of Heidelberg in Germany recently reported a complete response in two patients treated with Ac-225-PSMA-617 (see this link). … READ MORE …